title: Bone marrow transplantation of chronic myelogenous leukemia in chronic phase: evaluation of risks and benefits.
abstract: OBJECTIVE
  Allogeneic bone marrow transplantation (BMT) is an option for some patients with chronic myelogenous leukemia (CML). We retrospectively evaluated the effect of various risk factors observed at diagnosis and at transplantation on survival, event-free survival (EFS), and relapse after BMT.
  
  
  METHODS
  Seventy-nine patients with CML in chronic phase (CP) were treated with cyclophosphamide and total body irradiation followed by BMT. Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporine (CsA) in most instances or CsA plus the use of lymphocyte-depleted bone marrow (BM).
  
  
  RESULTS
  Survival at 4.5 years was 52%. Stratified by age and GVHD prophylaxis, the actuarial survival was 65% (95% confidence interval [CI], 47% to 78%) in patients aged less than 30 years receiving unmanipulated BM, 33% (95% CI, 12% to 56%) in patients greater than or equal to 30 years old receiving unmanipulated BM, and 38% (95% CI, 14% to 63%) in patients greater than or equal to 30 years old receiving lymphocyte-depleted BM. In univariate analysis, patient age (greater than or equal to 30 years) and the use of lymphocyte-depleted BM negatively influenced EFS. When stratified by age and GVHD prophylaxis, however, ABO incompatibility, cytomegalovirus (CMV) seropositivity, and chronic GVHD significantly reduced the probability of EFS. Factors that have been associated with early death in nontransplanted patients (ie, sex, spleen size, blast and platelet counts at presentation) were not predictive of long-term survival outcome after BMT.
  
  
  CONCLUSIONS
  The data suggest that (1) BMT should be offered early after diagnosis to all patients with CML in CP who have compatible sibling donors regardless of prognostic factors at presentation, (2) GVHD remains the principal cause of mortality after BMT in patients receiving CsA, and (3) T-cell depletion by the physical separation method of counterflow elutriation (CE) is associated with a significant risk of relapse.
authors.affiliation: Bone Marrow Transplantation Unit, Johns Hopkins Oncology Center, Johns Hopkins University School of Medicine, Baltimore, MD.
authors.forename: J E
authors.initials: JE
authors.lastname: Wagner
authors.forename: M
authors.initials: M
authors.lastname: Zahurak
authors.forename: S
authors.initials: S
authors.lastname: Piantadosi
authors.forename: R B
authors.initials: RB
authors.lastname: Geller
authors.forename: G B
authors.initials: GB
authors.lastname: Vogelsang
authors.forename: J R
authors.initials: JR
authors.lastname: Wingard
authors.forename: R
authors.initials: R
authors.lastname: Saral
authors.forename: C
authors.initials: C
authors.lastname: Griffin
authors.forename: N
authors.initials: N
authors.lastname: Shah
authors.forename: B A
authors.initials: BA
authors.lastname: Zehnbauer
mesh_terms: D000293:Adolescent; D000328:Adult; D000704:Analysis of Variance; D016026:Bone Marrow Transplantation / Q000379:methods; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000627:therapeutic use; D016572:Cyclosporine / Q000627:therapeutic use; D005260:Female; D006086:Graft vs Host Disease / Q000517:prevention & control; D006801:Humans; D015466:Leukemia, Myeloid, Chronic-Phase / Q000601:surgery* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012189:Retrospective Studies; D012307:Risk Factors; D016019:Survival Analysis; D014916:Whole-Body Irradiation
chemical_list: D016572:Cyclosporine; D003520:Cyclophosphamide